CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Favorable regulatory scenario
3.5.1.2. Increase in geriatric population
3.5.1.3. Rise in incidence of chronic diseases

3.5.2. Restraints

3.5.2.1. Availability of alternative therapies
3.5.2.2. Drug exploitation
3.5.2.3. Patent expiration of prescription drugs

3.5.3. Opportunities

3.5.3.1. Advancements in drug development
3.5.3.2. Untapped markets in developing economies

CHAPTER 4 PAIN MANAGEMENT DRUGS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NSAIDS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ANESTHETICS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. ANTICONVULSANTS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. ANTI-MIGRAINE AGENTS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ANTIDEPRESSANTS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. OPIOIDS

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Tramadol
4.7.5. Hydrocodone
4.7.6. Oxycodaone
4.7.7. Others

4.8. NON-NARCOTIC ANALGESICS

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ARTHRITIC PAIN

5.2.1. Market size and forecast

5.3. NEUROPATHIC PAIN

5.3.1. Market size and forecast

5.4. CANCER PAIN

5.4.1. Market size and forecast

5.5. CHRONIC BACK PAIN

5.5.1. Market size and forecast

5.6. POST-OPERATIVE PAIN

5.6.1. Market size and forecast

5.7. MIGRAINE

5.7.1. Market size and forecast

5.8. FIBROMYALGIA

5.8.1. Market size and forecast

CHAPTER 6 PAIN MANAGEMENT DRUGS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast by country
6.2.4. Market size and forecast by drug class
6.2.5. Market size and forecast by indications

6.2.5.1. U.S. market size and forecast by drug class
6.2.5.2. U.S. market size and forecast by indication
6.2.5.3. Canada market size and forecast by drug class
6.2.5.4. Canada market size and forecast by indication
6.2.5.5. Mexico market size and forecast by drug class
6.2.5.6. Mexico market size and forecast by indication

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast by country
6.3.4. Market size and forecast by drug class
6.3.5. Market size and forecast by indication

6.3.5.1. UK market size and forecast by drug class
6.3.5.2. UK market size and forecast by indication
6.3.5.3. France market size and forecast by drug class
6.3.5.4. France market size and forecast by indication
6.3.5.5. Germany market size and forecast by drug class
6.3.5.6. Germany market size and forecast by indication
6.3.5.7. Italy market size and forecast by drug class
6.3.5.8. Italy market size and forecast by indication
6.3.5.9. Spain market size and forecast by drug class
6.3.5.10. Spain market size and forecast by indication
6.3.5.11. Rest of Europe market size and forecast by drug class
6.3.5.12. Rest of Europe market size and forecast by indication

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast by country
6.4.4. Market size and forecast by drug class
6.4.5. Market size and forecast by indications

6.4.5.1. Japan market size and forecast by drug class
6.4.5.2. Japan market size and forecast by indication
6.4.5.3. China market size and forecast by drug class
6.4.5.4. China market size and forecast by indication
6.4.5.5. Australia market size and forecast by drug class
6.4.5.6. Australia market size and forecast by indication
6.4.5.7. South Korea market size and forecast by drug class
6.4.5.8. South Korea market size and forecast by indication
6.4.5.9. India market size and forecast by drug class
6.4.5.10. India market size and forecast by indication
6.4.5.11. Taiwan market size and forecast by drug class
6.4.5.12. Taiwan market size and forecast by indication
6.4.5.13. Rest of Asia-Pacific market size and forecast by drug class
6.4.5.14. Rest of Asia-Pacific market size and forecast by indication

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast by country
6.5.4. Market size and forecast by drug class
6.5.5. Market size and forecast by indication

6.5.5.1. Brazil market size and forecast by drug class
6.5.5.2. Brazil market size and forecast by indication
6.5.5.3. South Africa market size and forecast by drug class
6.5.5.4. South Africa market size and forecast by indication
6.5.5.5. Saudi Arabia market size and forecast by drug class
6.5.5.6. Saudi Arabia market size and forecast by indication
6.5.5.7. Rest of LAMEA market size and forecast by drug class
6.5.5.8. Rest of LAMEA market size and forecast by indication

CHAPTER 7 COMPANY PROFILES

7.1. NOVARTIS AG

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments

7.2. ELI LILLY & COMPANY

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. ABBOTT LABORATORIES, INC.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. ENDO HEALTH SOLUTIONS, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments

7.5. PURDUE PHARMA L.P.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments

7.6. PFIZER, INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments

7.7. F. HOFFMANN LA ROCHE LTD.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments

7.8. MERCK & CO. INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments

7.9. JOHNSON & JOHNSON

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. GLAXOSMITHKLINE PLC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments